Meningococcal vaccine groups A and C conjugate - Aventis Pasteur

Drug Profile

Meningococcal vaccine groups A and C conjugate - Aventis Pasteur

Latest Information Update: 06 Sep 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi pasteur
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Meningococcal group A infections; Meningococcal group C infections

Most Recent Events

  • 24 Dec 1999 Pasteur Mérieux Connaught is now a subsidiary of Aventis and its new name is Aventis Pasteur
  • 05 Oct 1999 New profile
  • 05 Oct 1999 Phase-II clinical trials for Meningococcal group A infections in Niger (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top